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findings from the ECLIPSE trial should
enhance our ability to help women make
the best choices about their health.
Miriam Santer
GP, Kinson Road Medical Centre,
Bournemouth.
E-mail: miriamcsanter@yahoo.co.uk
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nMRCGP exam
As I am now in my ST3 year and due to
complete GP training next August, I am
eligible to take my Clinical Skills
Assessment (CSA). But when?
Having entered GP training at ST2, I
completed 6 months in general practice
and 6 months in an innovative post during
my ST2 year. During ST3 I have 6 months
of paediatrics, followed by 6 months of
general practice. And there lies my
dilemma.
I could sit the CSA in October or
January/February, but at that time I’ll be
doing paediatrics. Although useful for my
general practice career, not the best
preparation for the CSA, as this will test a
much wider area of practice.
Option 2 is to sit the CSA in May. I’ll
be back in general practice by this time
so will have a chance to prepare properly
for the assessment. However, results
aren’t published until June, just 2 months
before I complete my training. I would
therefore be applying for jobs without
having completed my nMRCGP — would
I even be eligible for short-listing? And if I
don’t pass ... My training programme
complete but no nMRCGP. With the
expense and time involved in taking the
been shown to make a real difference.3
We congratulate our Australian colleagues
on their excellent work and are also
envious of the opportunities that they
have for substantial translational research
funding.
Chris Barclay
Academic Unit of Primary Medical Care,
University of Sheffield, Sheffield, S5 7AU.
E-mail: csbarclay@btinternet.com
Nigel Mathers
Professor, Academic Unit of Primary Medical
Care, University of Sheffield.
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In response to the article entitled ‘Can
type 2 diabetes be prevented in UK
general practice?’ published in the August
issue of the BJGP,1 we would like to
highlight our experience with diabetes
prevention.
In the Finnish Diabetes Prevention
Study,2 participants who successfully
achieved their lifestyle-change goals for
physical activity and diet did not go on to
develop diabetes after 7 years of follow-
up.3 To determine whether the results of
clinical trials could be reproduced in the
‘real world’ of primary care, the GOAL
Lifestyle Implementation Trial to prevent
Type 2 diabetes in primary health care,4 a
trial using a structured programme was
designed and trialled in Finland.
In 2004–2006, a sister project of GOAL
was run in the Greater Green Triangle
region of South Australia: the Greater
Green Triangle Diabetes Prevention
Programme (GGT DPP). This study
evaluated the feasibility of a structured
group programme for lifestyle modification
in Australian primary healthcare settings
CSA, I don’t want to just ‘give it a go’ in
January without feeling properly
prepared.
I am aware that other deaneries
schedule the whole of ST3 in general
practice, allowing trainees to choose from
all three sittings of the CSA. Perhaps a
sitting in mid-March for those of us doing
a more restrictive training programme?
Emma Thompson
GP ST3 trainee,
Darlington Memorial Hospital.
E-mail: emmacthompson@yahoo.co.uk
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Diabetes prevention
With the publication of several large
randomised controlled lifestyle change
trials showing benefit in delaying or
preventing progression from pre-diabetes
to type 2 diabetes, work has been taking
place in many locations to translate
research evidence into practical
interventions to improve the care of our
patients at the primary care level.
Laatikainen and colleagues are to be
congratulated in conducting the large
Diabetes Prevention Project in Australia.1
Like us, they successfully delivered a
structured programme to patients with
pre-diabetes using group work, delivering
education enhanced by motivational
techniques. Our programme was a
randomised controlled pilot study testing
two different dietary interventions.2 Theirs
recruited a larger number of pre-diabetic
participants and was able to show a
statistically significant effect in reducing
progression to type 2 diabetes compared
with baseline using an audit
methodology.
The biggest obstacle faced by many
working in this field, including ourselves,
is to secure adequate funding to develop
and refine such pragmatic intervention
programmes. This work is vital to the
wellbeing of our patients. Up to 90% of
people who develop diabetes may not
have done so had their lifestyle choices
been different, and interventions have
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(n = 237). The imputed reductions in the
risk of diabetes and cardiovascular
disease were 40% and 18% respectively.
All components of the metabolic
syndrome apart from systolic blood
pressure were improved. Intervention
components included information
provision, group discussions, self-
monitoring of behaviour, goal-setting, and
planning for behaviour change and
maintenance. Full details of the
intervention and its results have been
reported elsewhere.5
The success of the GGT DPP in
primary healthcare settings did not go
unnoticed. The Department of Human
Services in Victoria has already begun
implementing this programme on a large
scale, with the aim of having 25 000
Victorians reduce their risk of type 2
diabetes by 2011.
Nathalie Davis-Lameloise
Research Fellow, GGT UDRH, Flinders
University and Deakin University, PO Box 423
Warrnambool, Victoria 3280, Australia.
E-mail: Nathalie.Davis@greaterhealth.org
Benjamin Philpot
Research Associate, Flinders University and
Deakin University.
Prasuna Reddy
Professor and Director of Health Services
Research, Flinders University and Deakin
University.
James A Dunbar
Professor and Director of Greater Green
Triangle University, Flinders University and
Deakin University.
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not expecting someone to call our
financial judgement into question, and use
our letter to warn against APMS
contracts.
First, our defence: we made careful
calculations, agreed and accepted by the
appointing PCT. In addition, our bid price
was above the minimum recommended
by the BMA at the time. In that sense, we
believe that responsibility for the financial
judgement is a shared matter, and
directing criticism at one party unhelpful.
APMS contract setting continues to
evolve, and we understand that some
contracts are now approaching a fairer
reflection of what is needed to provide
high quality care in the local context. If
this continues, then APMS may yet
become an effective vehicle for redressing
the inequity of resource we observed in
our original letter.
That said, Dr Zuckerman makes a valid
point about caveat emptor. Our
experience shows the real risks that a
single practice faces when bidding for an
APMS contract. By comparison, large
commercial organisations can probably
write off the loss of an underfunded
contract for several years, so as to get
their foot in the door.
This, however, creates a dilemma: for
existing practices to sit on their hands
while commercial organisations harvest
large swathes of primary care, or to seek
to preserve the qualities of continuity and
professionalism that characterise general
practice by exposing themselves to risk.
Judging the effects on health inequalities
of action versus inaction is difficult. The
logical alternative — for large groups of
independent practices to form
partnerships to increase their clout — still
seems too unappealing for most GPs to
follow it through.
No one held a gun to our heads, but
our sense of threat to general practice
was and remains strong. We chose to act
by applying for this contract. Despite the
financial challenge, the practice team
remains positive. The majority of our
patients are being treated by experienced
GP principals, not locums or salaried
doctors on short-term contracts. Had we
been over-inhibited by caveat emptor this
situation could be very different.
Prevention of type 2 diabetes by lifestyle intervention
in an Australian primary health care setting: Greater
Green Triangle (GGT) Diabetes Prevention Project.
BMC Public Health 2007; 7: 249.
DOI: 10.3399/bjgp08X376258
APMS contracts
I read Dr Conlon’s letter in your
September issue1 with some incredulity
and a great feeling of sympathy for those
of his employees who may have been
faced with redundancy or a loss of
earnings in order for the practice to avoid
a financial disaster. This was, after all, an
APMS contract for which he made a
successful bid at a price he felt was
appropriate for the services he was
offering. It is absolutely vital for any
practice or consortium to formulate a
sound business plan in advance of any
APMS contract bid to see if it is
economically viable. In this case, it clearly
was not. Full credit must go to the PCT, of
whom I am not acknowledged to be a
great admirer, for increasing the payments
to 85% when there was no contractual
obligation for them to do so.
I hope that this example serves as an
object lesson to all those practices who
may be tempted to make bids for APMS
contracts without doing the most basic
arithmetic. It is unfortunate that more GPs
today have not had the benefit of a
grounding in the Classics. If they had they
would understand the meaning of the
Latin expression caveat emptor.
Charles Zuckerman
Northfield Health Centre, 15 St Heliers Road,
Birmingham, B31 1QT.
E-mail: charles.zuckerman@blmc.co.uk
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Authors’ response
We wanted to trigger a debate on
resource inequality in health care, so were
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